Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Core Insights - Perspective Therapeutics, Inc. announced updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET, presented at the 2025 ASCO-GI symposium, indicating promising anti-tumor activity and a favorable safety profile [1][11] Clinical Trial Overview - The Phase 1/2a clinical trial is a multi-center open-label dose escalation and expansion study targeting patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapy [2] - As of January 10, 2025, all nine patients in the trial had completed treatments, with at least one post-treatment scan available for each [4] Treatment Efficacy - One patient experienced a confirmed objective response lasting 17 weeks, while two additional patients showed initial unconfirmed responses after treatment [5][6][7] - Three out of seven patients in Cohort 2 had investigator-assessed objective responses, with two responses occurring after the treatment period [7][8] Safety Profile - The treatment demonstrated a favorable safety profile, with no dose-limiting toxicities or serious adverse events reported since the study's initiation [8] - Adverse events observed were primarily grade 1 and 2, with no significant decline in renal function noted [8] Future Directions - The company plans to continue dose-finding studies for [212Pb]VMT-α-NET and is engaging with the FDA regarding dose escalation and further patient enrollment [11][13] - Perspective aims to leverage insights from this clinical program to enhance its pipeline and develop new targeted radiopharmaceutical therapies [11][15]